Trial Profile
A Randomised, Open-labelled, Active-controlled, Multinational, Dose-escalation Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (NNC0195-0092, Somapacitan) Compared to Daily Dosing of Norditropin SimpleXx in Children With Growth Hormone Deficiency
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Aug 2023
Price :
$35
*
At a glance
- Drugs Somapacitan (Primary) ; Somatropin
- Indications Somatotropin deficiency
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 18 Jun 2023 Results evaluating the model-based analysis of dose insulin-like growth factor-I (IGF-I) responses of once-weekly somapacitan compared to daily GH in pediatric patients with GHD, presented at the 105th Annual Meeting of the Endocrine Society.
- 31 Jul 2021 According to EudraCT record the trial status is completed in Spain.
- 17 Apr 2021 Results Pooled modelling analysis of data from ClinicalTrials.gov identifiers NCT01973244, NCT00936403 and NCT01706783 published in the Clinical Pharmacokinetics